Unlocking the Potential of Endocannabinoid System (ECS) Therapies with Tetra Pharm Technologies
Our fund invests in businesses that bring frontier medicines into the mainstream, and despite the industry’s volatility, our conviction is only growing. This conviction comes to life in companies like Tetra Pharm Technologies, a pioneering platform company. Founded in 2018 by Martin Rose and Jesper Breum — whose backgrounds with BioGen and Novo Nordisk bring decades of pharmaceutical experience — Tetra Pharm Technologies seeks to unlock the therapeutic potential of the central nervous system (CNS) and endocannabinoid system (ECS) for the treatment of neurological and psychiatric disorders. Tetra Pharm Technologies is based out of the famed Medicon Valley, Europe’s leading life science cluster spanning the Greater Copenhagen region as well as southern Sweden and home to the international research centres of pharmaceutical giants such as Novo Nordisk, Baxter, and Lundbeck.
Tetra Pharm Technologies has already launched Xatepa®, a sublingual spray available in Germany for chronic pain and MS symptoms. Revenues from products like Xatepa® are strategically reinvested into its clinical pipeline, which includes 11 promising assets such as TPT 0301, a treatment for chronic pain which, in preclinical trials, showed faster absorption and onset compared to the industry’s standard medium-chain triglyceride (MCT) oil formulations. Martin and Jesper bring the scientific rigour that will be essential for developing CNS and ECS focused medicines.
The rigorous R&D process behind Tetra Pharm Technologies’ products, led by Dr. Morten Allesø — formerly with Lundbeck and Novo Nordisk Engineering — mirrors the standards of major pharmaceutical companies. As physicians reduce opioid prescriptions in the wake of the opioid crisis, alternatives for pain management that target the central nervous system and endocannabinoid system have only scratched the surface of their potential. Tetra Pharm Technologies is honing its pipeline toward three key therapeutic areas: chronic pain, neuropsychiatry, and obesity, aligning with expanding public acceptance of cannabinoids as a medical treatment.
Martin and Jesper embody the Danish philosophy of hygge, emphasising mindfulness, the importance of good relationships, the well-being of the community, and working hard for each other. This focus on people and community is integral to Tetra Pharm Technologies’ vision and reminds us of its Old Norse roots meaning “protected from the outside world” — a fitting metaphor for a company protecting scientific integrity from political interference. We are incredibly excited to partner with Tetra Pharm Technologies as it unlocks the therapeutic potential of the CNS and ECS and contributes to a world of healing, acceptance, and, indeed, hygge.
